Publications

Kernick C, Chow L, Alejandro M, Li K, Foisey MG, Yang X, Hilburger C, Lu J, Wu L, McClellan A, Takacsi-Nagy O, Brajenovic R, Theberath NE, Fuentes EC, Lin E, Hartman A, Truong T, Lee JHJ, Workley L, Ha AS, Ji Y, Putnam N, Andronikou N, Fatima N, Dotson M, Wong KA, Burns CH, Engelhard FAS, Stoyanova E, Vukovic M, Adie T, Lim WA, Roybal K, Santostefano K, Almeida R, Allen GM, Shy BR, Roth TL. Ultra-large targeted DNA integrations in primary human cells. bioRxiv : the preprint server for biology. 2026. PMID: 41993426

Nguyen DH, Bruck M, Rosenbluth JM. A Shape Analysis Algorithm Quantifies Spatial Morphology and Context of 2D to 3D Cell Culture for Correlating Novel Phenotypes with Treatment Resistance. bioRxiv : the preprint server for biology. 2026. PMID: 41993544

Bhalgat A, Micin K, Affer M, Ayupe AC, Gomez I, Schatz JH, Stelekati E, Williams S, Komanduri K, Wieder E, Cocco E, Taylor J. CIPHER-seq enables intracellular multimodal profiling of cytokine responses in single immune cells. Scientific Reports. 2026. PMID: 41951681

Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim DM, Mukherjee E, Krantz MS, Yao L, Johnson DB, Phillips EJ, Balko JM, Mohindra R, Quandt Z. irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets. EBioMedicine. 2026. PMID: 41951517

Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Díaz A, Llarch N, Iserte G, Mollà M, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal A, Vogel A, Yanagihara TK, Ayuso C, Torres F, Bruix J. Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654]. Journal of hepatology. 2026. PMID: 41936510

Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS. Corrigendum to "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer" [The Breast 86 (2026) 104744]. Breast (Edinburgh, Scotland). 2026. PMID: 41936467

Sleeper O, Fortino J, Cho NW, Daud AI, Tsai KK, Lee JC, Alvarado M, Maker AV, Liu L, Kim C, Chan JW. Longitudinal tumor-informed ctDNA monitoring for recurrence and treatment response in melanoma. BMC cancer. 2026. PMID: 41928167

Lee G, Haugg F, Bontempi D, He J, Bitterman DS, Pai S, Guthier C, Fitzgerald KJ, Kozono DE, Kann BH, Aerts HJWL, Mak RH. Multimodal Assessment of Biological Age Following Radiation Therapy Among Patients With Early-Stage NSCLC. JAMA network open. 2026. PMID: 41949867

Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ. Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British journal of cancer. 2026. PMID: 41699262

Fann JR, Vanderlan J, Brewer BW, Corbett C, Keller J, Lahijani S, Niazi SK, Riba MB, Andersen B, Atreya CE, Braun I, Breitbart WS, Channa Y, Farabelli J, Fleishman S, Garcia S, Greenberg DB, Handzo RGF, Horyna A, Huang CH, Hutchinson S, Johns S, La Cava S, Leeper H, Martin S, Mukherjee D, Pailler M, Parnes F, Rao V, Rocha-Cadman X, Scher E, Schuster J, Thompson LMA, Usher A, Valentine AD, Montgomery S, Darlow S. NCCN Guidelines® Insights: Distress Management, Version 1.2026. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41956112

Chang HL, Kang IM, Rugo HS. Eribulin and trastuzumab in early-line HER2-positive metastatic breast cancer: evaluating an active chemotherapy partner in an evolving treatment landscape. Chinese clinical oncology. 2026. PMID: 42145010

Yogo A, Akanuma N, Kim GE, Paciorek A, Zhang L, Le P, Hirose K, Corvera CU, Bergsland EK, Nakakura EK. Characterization of small intestinal neuroendocrine tumorlets. Endocrine-related cancer. 2026. PMID: 41886547

Riely GJ, Wood DE, Aisner DL, Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Levy B, Lin J, Loo BW, Lovly CM, Maldonado F, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patil T, Polanco PM, Riess J, Mendez ALR, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yau E, Yun K, Gregory K, Hang L. Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41956107

Rauschecker A, Romano M, Wei J, Girma S, Beheshtian E, Nedelec P, Eghbali R, Sugrue L, Rubenstein JL. YIA26-002: Automated Segmentation and Radiogenomic Analysis of Primary CNS Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41991092

Bowers JT, Vijayanarayanan A, Gill N, Traglia M, Thomas R, Andreadis CB, Ai WZ, Ho C, Kaplan LD, Merrill MH, Seshadri MR, Randall MP, Rubenstein JL, Ganapathi K, Prakash S, Devine WP, Spinner MA. CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS). Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41921576

Bowers JT, Vijayanarayanan A, Gill N, Traglia M, Thomas R, Andreadis CB, Ai WZ, Ho C, Kaplan LD, Merrill MH, Seshadri MR, Randall MP, Rubenstein JL, Ganapathi K, Prakash S, Devine WP, Spinner MA. CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS). Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41991041

Walling AM, Sak R, Skootsky S, Wenger N, Balabanova N, Friedberg N, Villalona-Calero M, Schwartz G, Singha S, Bray-Hanin L, Anand S, Jagels B, Dahm L, Cabrera M, Bresnahan A, Meyers B, Sonderlund M, Nelson E, Senthil M, Kane S, Hamdan A, Vu P, Venook A, Burgess D, Gold K. BIO26-035: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41911852

Walling AM, Sak R, Skootsky S, Wenger N, Balabanova N, Friedberg N, Villalona-Calero M, Schwartz G, Singha S, Bray-Hanin L, Anand S, Jagels B, Dahm L, Cabrera M, Bresnahan A, Meyers B, Sonderlund M, Nelson E, Senthil M, Kane S, Hamdan A, Vu P, Venook A, Burgess D, Gold K. BIO26-035: Validation of an Electronic Health Record Phenotype for Advanced Solid Cancer Across Five University of California Health Systems. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41991066

Schwartzberg L, Crawford J, Baird J, Crist K, Marino V, Shah N, Franklin H. CLO26-092: Real-World Use of Eflapegrastim in 14-Day Chemotherapy Cycles/Dose-Dense Regimens. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 42061425

Schwartzberg L, Crawford J, Baird J, Crist K, Marino V, Shah N, Franklin H. CLO26-092: Real-World Use of Eflapegrastim in 14-Day Chemotherapy Cycles/Dose-Dense Regimens. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41911759